Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
Tolerability of home subcutaneous immunoglobulin (ScIG) for replacement therapy for
hypogammaglobulinemia in allogeneic HCT patients. A financial analysis comparing the cost of
ScIG with intravenous immunoglobulin (IVIG) will also be performed.